SNP genotyping is the quantitative measurement of specific genetic differences between members of a given species. It is basically a sub-type of quantitative genomics, which is also the measurement of overall genetic variance. SNPs are among the most prevalent kinds of genetic differences. They can be used in studies of human disease and even in the development of various laboratory mice and rats. As far as regional impact, North America seems to be gaining significant growth in the SNP genotyping and analysis market. This is due to favorable government policies towards proper diagnosis and availability of better R&D facilities in the U.S. and Canada. Furthermore, Asia Pacific is likely to register a positive outlook due to increasing demand for personalized medicines and rising disposable income.
Over the years, the prevalence of genetic disorders such as Down syndrome, cystic fibrosis, Apert syndrome, and more has increased significantly, which has surged the demand for SNP genotyping. As per the Cystic Fibrosis Foundation (CFF), over 1,000 new cases of cystic fibrosis are diagnosed each year in the U.S. SNP genotyping is typically used to identify disease-causing genes and to understand inter-individual variation in drug response. Hence, such factors can stimulate the growth of the SNP genotyping and analysis market.
Some recent developments in the field of SNP genomics have brought about some exciting methods for estimating the genotype of any individual. One method called polygenic scorecards estimates the probability that a locus will generate a specific trait given its ancestral state. That being said, certain factors can pose challenges in the development of the market. For instance, a lack of proper standardization in SNP processes can limit the adoption of SNP genotyping. Besides, privacy concerns can further impede the growth of the SNP genotyping and analysis market.
Another method of SNP genomics that is gaining popularity is whole genome sequencing or DNA profiling. This method can generate a large number of DNA variations that can be compared to the coding region of the genes. SNPs can also be compared to study cases of the disease for which linkage studies were performed. Another key factor augmenting the growth of the market in discussion is increased multiplexing capacity. It has led to increased application of SNP genotyping and analysis. With the ability to convert hundreds of PCR primer pairs into single-tube, the SNP genotyping is proving to be critical. Thus, these factors can augment the growth of the SNP genotyping market. Recently, in September 2020, NRGene launched SNPer, a new product to allow genotyping optimization at lower costs.